From April 6 to 8, Seegene participated in the Regensburger Meeting of Applied Molecular Diagnostics (ReMMDi) 2017, held at University Hospital Regensburg in Germany.

Held every second year, ReMMDi is a major conference on molecular diagnostics in Germany. The conference’s major topics include cutting-edge molecular diagnostic techniques and epidemiology for not only multidrug-resistant bacteria, such as MRSA and VRE, but also the management of major causes of microbial infections, such as Clostridium difficile (causes enteritis and diarrhea).

At the conference, Seegene’s Dusseldorf-based German branch introduced the Allplex™ Respiratory and Gastrointestinal Panel Assays, which enable the selective screening of pathogen panels based on disease and/or symptom of patient, highlighting the superiority of Seegene’s high multiplex real-time PCR technology. Seegene also presented the results of clinical evaluations conducted by major institutions in Europe for its Allplex™ products and highlighted some of the positive experiences that users have had with the products, receiving significant attention from representatives of hospital laboratories and test centers interested in acquiring a multiplex molecular diagnostics system at a ReMMDi workshop.

Earlier this year, the WHO announced a global priority pathogens list (global PPL), which identifies the pathogens that are expected to have the greatest impact on the health of humanity. The creation of this list has led to the designation of the prevention and management of antibiotic-resistant bacteria as one of the most urgent tasks for the health sector worldwide.

Dr. Lothar Kruska, the president of Seegene Germany, said, “By passing a new legislative bill on the prevention of antibiotic-resistant bacteria, the German government has made it very clear that the comprehensive diagnosis of infectious pathogens will form the basis for prompt and effective treatment as well as the prevention of the indiscriminate use of antibiotics. By supplying hospital laboratories and test centers with multiplex molecular diagnostics products capable of ensuring the accurate prescription of the proper antibiotics for each causal pathogen, Seegene is contributing to the effort to address and control the problem of antibiotic-resistant bacteria in Germany.”